

Optimization of 5-ASA Therapies in IBD

Chair:

Maria T. Abreu, MD

Mount Sinai School of Medicine
New York, New York

A Satellite Symposium at the 2006 CCFA National Research & Clinical Conference –
5th Annual Advances in the Inflammatory Bowel Diseases

Saturday, December 2, 2006
Miami, Florida

Loews Miami Beach Hotel
3:40 pm - 5:00 pm
Americana Salon 4

Optimization of 5-ASA Therapies in IBD

Saturday, December 2, 2006
Miami, Florida

Scientific Agenda

- 3:40 pm Welcome
Maria T. Abreu, MD
- 3:45 pm How emphasis on compliance plays a role in selecting 5-ASA therapies
Russell D. Cohen, MD
- 4:05 pm Development of 5-ASA therapies: Effect on inflammation and impact of mucosal healing in IBD
Asher A. Kornbluth, MD
- 4:25 pm Panel case discussion: Determining ASA therapies to achieve optimal outcomes
Maria T. Abreu, MD
- 4:45 pm Questions and answers
- 5:00 pm Adjourn and reception

Confirmed Faculty

Maria T. Abreu, MD
Mount Sinai School of Medicine
New York, New York

Russell D. Cohen, MD
University of Chicago
Medical Center
Chicago, Illinois

Asher A. Kornbluth, MD
Mount Sinai School of Medicine
New York, New York

Symposium Organizer



4325 Alexander Drive
Alpharetta, Georgia
30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
www.imedex.com

Corporate Support



This symposium is made possible by an unrestricted educational grant from Shire.

Shire has been assigned meeting space to support an educational offering during the 5th Annual Advances in the Inflammatory Bowel Diseases conference.

The assignment of meeting space does not imply product endorsement nor does Advances in IBD assume responsibility for the educational content.

Who Should Attend

This educational symposium is intended for gastroenterologists, internists, and other health care professionals in active clinical practice involving the management of patients with Inflammatory Bowel Diseases (IBD).

Educational Objectives

After successful completion of this activity, participants should be able to:

- ➔ Discuss the role of compliance when selecting 5-ASA therapies for IBD
- ➔ Recognize newer 5-ASA therapies and their ability to increase compliance
- ➔ Improve patient outcomes by optimizing selection of 5-ASA therapies

Physicians

Imedex®, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, Inc. designates this educational activity for a maximum 1.50 of *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

This program (1206C) has been approved by an AACN Certification Corporation-approved provider (Provider # 00013328) under established AACN Certification Corporation guidelines for a maximum of 1.5 contact hours, CERP Category A.

Registration

No pre-registration for this symposium is required.

Please register for the "2006 CCFR National Research & Clinical Conference – 5th Annual Advances in the Inflammatory Bowel Diseases" at: www.advancesinibd.com